Evidence map›Paper›PMID 25702057›Full record

ReviewCurrent atherosclerosis reports2015

Treatment of dyslipidemia in HIV.

Rajagopal V Sekhar

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current atherosclerosis reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Navigating Lipodystrophy: Insights from Laminopathies and Beyond.International journal of molecular sciences · 2024
    Review
  2. Article
  3. Review
  4. Choosing statins: a review to guide clinical practice.Archives of endocrinology and metabolism · 2021
    Review
  5. Article
  6. Article
  7. Evidence-based review of statin use in patients with HIV on antiretroviral therapy.Journal of clinical & translational endocrinology · 2017
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Rajagopal V SekharBCM-185, Translational Metabolism Unit, Division of Diabetes, Endocrinology and Metabolism, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030-2600, USA, rsekhar@bcm.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients infected with HIV have a high risk of developing dyslipidemia. Effective therapeutic strategies can be challenging due to an increase risk of drug interactions and other comorbidities. Understanding the underlying pathophysiology and the principles of pharmacological and non-pharmacological therapeutic interventions can be of value in the appropriate management of dyslipidemia in the HIV-infected patient.

Indexed as

Diet TherapyExercise TherapyAnticholesteremic AgentsAnti-HIV AgentsAzetidinesCholesterol, HDLCholesterol, LDLDyslipidemiasEzetimibeFatty Acids, NonesterifiedFatty Acids, Omega-3Fibric AcidsGlutathioneGrowth Hormone-Releasing HormoneHIV InfectionsHuman Growth HormoneacipimoxAnticholesteremic AgentsAnti-HIV AgentsAzetidinesCholesterol, HDLCholesterol, LDLEzetimibeFatty Acids, NonesterifiedFatty Acids, Omega-3Fibric AcidsGlutathioneGrowth Hormone-Releasing HormoneHuman Growth HormoneHydroxymethylglutaryl-CoA Reductase InhibitorsLeptinNiacinPyrazinestesamorelinThiazolidinedionesTriglycerides

Identifiers

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.